DK0465508T3 - Diætsupplement til insulinresistente diabetikere - Google Patents

Diætsupplement til insulinresistente diabetikere

Info

Publication number
DK0465508T3
DK0465508T3 DK90905048T DK90905048T DK0465508T3 DK 0465508 T3 DK0465508 T3 DK 0465508T3 DK 90905048 T DK90905048 T DK 90905048T DK 90905048 T DK90905048 T DK 90905048T DK 0465508 T3 DK0465508 T3 DK 0465508T3
Authority
DK
Denmark
Prior art keywords
dietary supplement
insulin resistant
development
diabetics
resistant diabetics
Prior art date
Application number
DK90905048T
Other languages
English (en)
Inventor
Joseph Larner
Allison Kennington
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia filed Critical Univ Virginia
Application granted granted Critical
Publication of DK0465508T3 publication Critical patent/DK0465508T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A23L29/37—Sugar alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK90905048T 1989-03-08 1990-03-08 Diætsupplement til insulinresistente diabetikere DK0465508T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32048289A 1989-03-08 1989-03-08
PCT/US1990/001109 WO1990010439A1 (en) 1989-03-08 1990-03-08 Dietary supplement for insulin-resistant diabetics

Publications (1)

Publication Number Publication Date
DK0465508T3 true DK0465508T3 (da) 2000-08-07

Family

ID=23246630

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90905048T DK0465508T3 (da) 1989-03-08 1990-03-08 Diætsupplement til insulinresistente diabetikere

Country Status (10)

Country Link
US (1) US5124360A (da)
EP (1) EP0465508B1 (da)
JP (3) JPH04504847A (da)
AT (1) ATE193440T1 (da)
AU (1) AU647735B2 (da)
CA (1) CA2047686C (da)
DE (1) DE69033560T2 (da)
DK (1) DK0465508T3 (da)
ES (1) ES2146197T3 (da)
WO (1) WO1990010439A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428066A (en) * 1989-03-08 1995-06-27 Larner; Joseph Method of reducing elevated blood sugar in humans
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
JPH06504278A (ja) * 1991-01-23 1994-05-19 ユニヴァーシティ　オヴ　ヴァージニア　アラムナイ　パテンツ　ファウンデイション ヒトの高い血糖値を低下させる方法
JPH0665080A (ja) * 1992-03-10 1994-03-08 Godo Shiyusei Kk α−グルコシダ−ゼ阻害剤を含有する、過血糖付随疾患の予防・治療剤、および保健食
US5420108A (en) * 1992-09-14 1995-05-30 Shohet; Isaac H. Method of controlling diabetes mellitus
TW282398B (da) * 1993-12-22 1996-08-01 Bristol Myers Squibb Co
US5652221A (en) * 1994-11-07 1997-07-29 The University Of Virginia Patent Foundation Method of treating defective glucose metabolism using synthetic insulin substances
US5550166A (en) * 1995-03-17 1996-08-27 Ostlund; Richard E. Pinitol and derivatives thereof for the treatment of metabolic disorders
US6086882A (en) 1997-08-06 2000-07-11 National Institute For Pharmaceutical Research Phytodrug for management of peptic ulcer and methods of preparing and using same
DE19707756A1 (de) * 1997-02-26 1998-08-27 Georgios Dr Pandalis Präparat auf der Basis von Kichererbsenpflanzen oder -pflanzenteilen
JP2001521551A (ja) * 1997-03-24 2001-11-06 ガルデルマ リサーチ アンド デヴェロップメント エス エヌ セ インスリン非依存性糖尿病の治療のためのレチノイド関連分子
US6492341B1 (en) 1997-05-07 2002-12-10 Cornell Research Foundation, Inc. Preparation of fagopyritols and uses therefor
CA2236641C (en) * 1997-05-07 2008-07-15 Cornell Research Foundation, Inc. Preparation of fagopyritols and uses therefor
US20010039297A1 (en) * 1998-05-19 2001-11-08 Insmed Pharmaceuticals, Inc. Compositions and method for improving insulin sensivity and glucose metabolism in individuals with impaired fasting glucose or impaired glucose tolerance
EP1183021A4 (en) 1999-05-20 2004-09-15 Humanetics Corp STIMULATION OF GLUCOSE TRANSPORT IN ANIMAL TISSUE BY ADMINISTRATION OF PINITOL
US6784209B1 (en) * 1999-10-18 2004-08-31 Muscletech Research And Development Inc. Food supplement for increasing lean mass and strength
JP2003511094A (ja) * 1999-10-18 2003-03-25 マッスルテク リサーチ アンド ディヴェロプメント インコーポレーション 無脂肪体重及び体力を増強するための食物補充物質
AU2001239826B2 (en) * 2000-02-23 2006-06-15 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
KR20010091341A (ko) * 2000-03-14 2001-10-23 신용철 카이로이노시톨 추출물을 유효성분으로 함유하는 의약조성물
US6660891B2 (en) 2000-05-15 2003-12-09 Insmed Incorporated Methods for the production of D-chiro-inositol and the use of D-chiro inositol obtained therefrom
US6492339B1 (en) * 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
US6486127B1 (en) * 2001-05-23 2002-11-26 Insmed, Incorporated Compositions comprising D-chiro inositol and lipid lowering compounds and methods of treatment thereof
JP2006501859A (ja) 2002-05-09 2006-01-19 コーネル リサーチ ファンデーション， インコーポレーティッド ファゴピリトールシンターゼ遺伝子およびその使用法
US20060258754A1 (en) * 2004-05-28 2006-11-16 Joseph Larner Method of treating endothelial dysfunction, oxidative stress and related diseases
US20060004096A1 (en) * 2004-05-28 2006-01-05 Joseph Larner Method of Treating Endothelial Dysfunction, Oxidative Stress and Related Diseases
JP2007068476A (ja) * 2005-09-08 2007-03-22 Hokko Chem Ind Co Ltd 健康食品およびｄ−キロ−イノシトールを得る方法
US20080103116A1 (en) * 2006-11-01 2008-05-01 Jennings-Spring Barbara L Method of treatment and compositions of D-chiro inositol and phosphates thereof
US20090214474A1 (en) * 2006-11-01 2009-08-27 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AR074797A1 (es) * 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
ITMI20110445A1 (it) * 2011-03-22 2012-09-23 Lo Li Pharma Srl Formulazione farmaceutica comprendente inositolo.
US10933001B2 (en) 2016-04-27 2021-03-02 Kobayashi Pharmaceutical Co., Ltd. Hair growth agent
JP6838146B2 (ja) 2016-10-06 2021-03-03 ディーワイ ナチュラル カンパニー リミテッド ピニトール、ｄ−カイロ−イノシトール、又はこれらの類似化合物を有効成分として含む、女性の更年期症状の改善、予防、又は治療用の組成物
US11898184B2 (en) 2017-09-07 2024-02-13 Sweet Sense Inc. Low glycemic sugar composition
BR112020010343A2 (pt) 2017-11-23 2020-11-10 Biosearch, S.A. método para aumentar taxa de implantação de embrião em um paciente feminino sofrendo de síndrome de ovário policístico

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE465951B (sv) * 1984-10-23 1991-11-25 Perstorp Ab Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav
SE464059C (sv) * 1988-09-15 1997-06-02 Perstorp Ab Användning av inositoltrifosfat för framställning av läkemedel
JPH03138126A (ja) * 1989-10-24 1991-06-12 Mitsubishi Gas Chem Co Inc 均一薄肉中空成形品の射出成形方法

Also Published As

Publication number Publication date
DE69033560D1 (de) 2000-07-06
AU5280890A (en) 1990-10-09
JP2002249427A (ja) 2002-09-06
CA2047686A1 (en) 1990-09-09
ES2146197T3 (es) 2000-08-01
EP0465508A1 (en) 1992-01-15
DE69033560T2 (de) 2001-03-01
JPH04504847A (ja) 1992-08-27
ATE193440T1 (de) 2000-06-15
EP0465508B1 (en) 2000-05-31
JP2000219624A (ja) 2000-08-08
US5124360A (en) 1992-06-23
CA2047686C (en) 2000-09-05
WO1990010439A1 (en) 1990-09-20
EP0465508A4 (en) 1992-05-13
AU647735B2 (en) 1994-03-31

Similar Documents

Publication Publication Date Title
DK0465508T3 (da) Diætsupplement til insulinresistente diabetikere
Sullivan Jr et al. Acute carbamazepine toxicity resulting from overdose
DK642587D0 (da) Insulinpraeparat
ES2060199T3 (es) Forma galenica para administrar oralmente glipicida hipoglicemica.
Field et al. Effect of salicylate infusion on plasma-insulin and glucose tolerance in healthy persons and mild diabetics
Goodhart et al. The role of nutritional deficiencies in the production of cardiovascular disturbances in the alcohol addict
Craig et al. Infants, toddlers, and aspirin
Nayyar et al. Fixed drug eruption to oxyphenbutazone and phenylbutazone
Melander et al. Clinical pharmacology of glipizide
Alderman Analgesics in the acute phase of myocardial infarction
Schwartz et al. Pentamidine-associated pancreatitis
SHIGETA et al. Effect of coenzyme Q7 treatment on blood sugar and ketone bodies of diabetics
Miller Hypoghycaemic effect of oxytetracycline.
Hultgren et al. Clinical and experimental study of use of khellin in treatment of angina pectoris
ZIEVE et al. Vitamin unresponsiveness: progression of classic signs of neuropathy and pellagra during therapy
Friedemann et al. Work at high altitude; utilization of thiamin and riboflavin at low and high dietary intake; effect of work and rest.
Rachmilewitz et al. Electrocardiographic changes and the effect of niacin therapy in pellagra
Begg Sulphaemoglobinaemia
JPS56108712A (en) Lecithin cholesterol acyl transferase activator
Wilhelmsen Beta-blockers and plasma triglycerides.
ROBINSON et al. THE THERAPEUTIC USE OF DIGITALIS: WITH ESPECIAL REFERENCE TO ITS INTRAVENOUS INJECTION
Alván et al. The validity of the sigmoid Emax model and efficiency concept in diuretic studies.
Leövey et al. Atypical clinical features of hypo-and hyperthyroidism in elderly age
Fulton et al. Intravascular Haemolysis and Acute Renal Failure Induced by Nomifensine
OSTRIC CLINICAL FEATURES OF AN EPIDEMIC OF VIRAL HEPATITIS IN BOSANSKA POSAVINA